摘要
目的探讨瑞舒伐他汀对非ST段抬高的急性冠脉综合征(ACS)经皮冠脉支架植入(PCI)患者术后血清炎症因子及近期预后的影响。方法 90例非ST段抬高的ACS患者随机均分为瑞舒伐他汀负荷剂量组(A组,20mg/d)、瑞舒伐他汀常规剂量组(B组,10mg/d)和阿托伐他汀组(C组,20mg/d),测定术前和术后24h血清内皮素1(ET-1)、基质金属蛋白酶9(MMP-9)、超敏C反应蛋白(hsCRP)的变化,随访6个月心脏不良事件的发生率。结果与术前比较,A、B、C组术后ET-1、MMP-9和hsCRP水平均增加,A组ET-1、MMP-9和hsCRP水平增幅小于B、C组(P<0.05)。A组术后6个月心脏不良事件发生率低于B组和C组(6.90%vs.13.3%和14.3%)(P<0.05和P<0.01)。结论早期应用负荷量瑞舒伐他汀可减少非ST段抬高的ACS患者PCI术后炎症因子的增加,降低术后6个月心脏不良事件发生率。
Objective To observe the the influence of rosuvastatin on serum inflammatory factors and short-term prognosis in the patients with non ST-elevation acute coronary syndrome（ACS）after percutaneous coronary stent implantation（PCI）.Methods Ninety patients were equally randomized into three groups of A（rosuvastatin 20 mg/d）,B（rosuvastatin 10 mg/d）and C（atorvastatin 20 mg/d）.Serum levels of endothelin-1（ET-1）,metalloproteinases-9（MMP-9）and hypersensitive C-reactive protein（hsCRP）were detected before and after PCI.The patients were followed up for 6months and the incidence of cardiac adverse events were recorded.Results Serum levels of ET-1,MMP-9and hsCRP after PCI in three groups were all increased compared to those before.The increases of serum ET-1,MMP-9and hsCRP after PCI were less in group A than those in groups of B and C（P〈0.05）.The incidence rate of cardiac adverse events in 6months after PCI was less in group A than that in groups of B and C（6.90% vs.13.3% and 14.3%）（P〈0.05 and P〈0.01）.Conclusion Early use of loading dose rosuvastatin treatment can attenuate the increases of serum inflammatory factors and reduce the incidence of cardiac adverse events in the patients with non ST-elevation ACS after PCI.
出处
《江苏医药》
CAS
2015年第4期439-441,共3页
Jiangsu Medical Journal
关键词
瑞舒伐他汀
经皮冠脉支架植入
炎症因子
Rosuvastatin
Percutaneous coronary stent implantation
Inflammatory factors
